Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? (Q36775256)

16 August 2017

1 reference

title

Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? (English)

1 reference

16 August 2017

William F C Rigby

1

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Nature Clinical Practice Rheumatology

16 August 2017

published in

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

227-233

1 reference

The biology of cachectin/TNF--a primary mediator of the host response

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

Anti-TNF therapy: where have we got to in 2005?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Recent advances in the treatment of the seronegative spondyloarthropathies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Impaired On/Off Regulation of TNF Biosynthesis in Mice Lacking TNF AU-Rich Elements

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Lethal Granuloma Disintegration in Mycobacteria-Infected TNFRp55-/- Mice Is Dependent on T Cells and IL-12

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Signal transduction by tumor necrosis factor and its relatives

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Infliximab treatment of sarcoidosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Clinical pharmacokinetics of TNF antagonists: how do they differ?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0438

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0438

1 reference

Dimensions Publication ID

16 August 2017

1038920460

0 references

1 reference